News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Tadataka “Tachi” Yamada, MD, PhD
Dr. Yamada had a distinguished career as a visionary leader in the life sciences industry. He led research and development at Takeda Pharmaceutical Co. and GlaxoSmithKline.
Funding Opportunity for Climate-Focused Faculty or Student Startups
Exelon Corporation and the non-profit Exelon Foundation are searching for promising early-stage companies to invest in for the 4th annual Climate Change Investment Initiative (2c2i).
President’s Innovation Prize Winner Lumify Care and PCI Startup Neuralert Hit Major Milestones in 2022
Lumify Care and Neuralert have grown rapidly in terms of funding and product expansion.
Penn Graduate Receives President’s Sustainability Prize for Robotics-Based System to Minimize Waste in Fishing Industry
Shinkei Systems cuts down on waste by reducing the likelihood that off-target species would be caught and killed, and streamlining the process to avoid waste.
New Penn Dental School Study Identifies Protein that Can Potentially Keep Bone Loss in Check
The research identifies the protein IFT80 as a key player in regulating populations of osteoclasts, cells that break down bone.
Penn Research on Chewing Gum that Could Reduce SARS-CoV-2 Transmission Enters Clinical Trial
Researchers are preparing to launch the first human trial to see how the gum affects active COVID-19 patients.
Penn-invented CAR-T Therapy Achieves Unprecedented Milestone
"We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me."
Former Fellow Dr. Rosa María Álvarez, PhD Guest Speaks for PCI Fellows Program
Rosa's experience working in the lab and participating in the PCI Fellows program at Penn helped her gain valuable experience for her career at Deloitte.
Cell and Gene Therapy On Track to Hit Record Number of Regulatory Approvals; Potential Implications for Commercial Real Estate Industry
While the CGT industry is growing at a rapid rate, real estate development happens much slower, which may have implications for the amount of available space.
Penn Spinout REGENXBIO Inc. Enters Commercial Phase; Focuses Gene Therapy on Common Cause of Blindness
Regenxbio's gene therapy would eliminate the need for wet AMD patients to visit their doctor every few months to receive a needle in their eye to treat their condition.